UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current use of CAR T cells to treat multiple myeloma

Hematology, 2023-12, Vol.2023 (1), p.340-347

2023

Volltextzugriff (PDF)

Aiming for the cure in myeloma: Putting our best foot forward

Blood reviews, 2023-11, Vol.62, p.101116-101116, Article 101116

2023

Volltextzugriff (PDF)

The Transition-State Structure for Human MAT2A from Isotope Effects

Journal of the American Chemical Society, 2017-10, Vol.139 (39), p.13754-13760

2017

Volltextzugriff (PDF)

Transition state analogue of MTAP extends lifespan of APCMin/+ mice

Scientific reports, 2021-04, Vol.11 (1), p.1-11, Article 8844

2021

Volltextzugriff (PDF)

Kinetic Isotope Effects and Transition State Structure for Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase from Plasmodium falciparum

Biochemistry (Easton), 2017-12, Vol.56 (48), p.6368-6376

2017

Volltextzugriff (PDF)

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Blood, 2024-07, Vol.144 (4), p.402-407

2024

Volltextzugriff (PDF)

Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications

Hemato, 2022-09, Vol.3 (3), p.454-465

2022

Volltextzugriff (PDF)

Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase

Journal of medicinal chemistry, 2019-04, Vol.62 (7), p.3286-3296

2019

Volltextzugriff (PDF)

Continuous Fluorescence Assays for Reactions Involving Adenine

Analytical chemistry (Washington), 2016-12, Vol.88 (23), p.11860-11867

2016

Volltextzugriff (PDF)

Heat Capacity Changes for Transition-State Analogue Binding and Catalysis with Human 5′-Methylthioadenosine Phosphorylase

ACS chemical biology, 2017-02, Vol.12 (2), p.464-473

2017

Volltextzugriff (PDF)

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

Blood advances, 2024-04, Vol.8 (7), p.1600-1611

2024

Volltextzugriff (PDF)

Microwave spectra, structure, and dynamics of the weakly bound complex, N2 CO2

The Journal of chemical physics, 2010-12, Vol.133 (24), p.244303-244303

2010

Volltextzugriff (PDF)

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Blood advances, 2024-06, Vol.8 (12), p.3246-3253

2024

Volltextzugriff (PDF)

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Blood advances, 2024-06, Vol.8 (12), p.3038-3044

2024

Volltextzugriff (PDF)

P962: COMMERCIAL TECLISTAMAB IN ANTI‐BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE

HemaSphere, 2023-08, Vol.7 (S3), p.e81198bb-n/a

2023

Volltextzugriff (PDF)

The Effects of Low‐Level Laser Light Exposure on Sperm Motion Characteristics and DNA Damage

Journal of andrology, 2012-05, Vol.33 (3), p.469-473

2012

Volltextzugriff (PDF)

Abstract 18: Doubled lifespan in APCMin/+ mice by targeting MTAP

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.18-18

2019

Volltextzugriff (PDF)

P-247 Increased WEE1 Expression Is Predictive of Short Progression-Free Survival, Independent of Standard Prognostic Factors in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S180-S180

2024

Volltextzugriff (PDF)

An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma

Blood cancer discovery, 2023-11, Vol.4 (6), p.433-436

2023

Volltextzugriff (PDF)

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.333-333

2023

Volltextzugriff (PDF)

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.1961-1961

2023

Volltextzugriff (PDF)

Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Blood, 2023-11, Vol.142 (Supplement 1), p.2024-2024

2023

Volltextzugriff (PDF)

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8049-8049

2023

Volltextzugriff (PDF)

OA-15 Maintenance Therapy Cessation for Multiple Myeloma Patients with Three-Year Sustained MRD Negative Remissions

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S10-S11

2024

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals 2020 Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(19)
Humans
(12)
Hematology
(8)
Animals
(5)
Biochemistry & Molecular Biology
(5)
Female
(5)
Kinetics
(4)
Male
(4)
Antibodies, Bispecific - Therapeutic Use
(3)
Purine-Nucleoside Phosphorylase - Metabolism
(3)
Rats
(3)
Actors
(2)
Adenine - Analogs & Derivatives
(2)
Adult
(2)
Aged
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Binding Sites
(2)
Biochemistry
(2)
Biological And Medical Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Current use of CAR T cells to treat multiple myeloma

Aiming for the cure in myeloma: Putting our best foot forward

The Transition-State Structure for Human MAT2A from Isotope Effects

Transition state analogue of MTAP extends lifespan of APCMin/+ mice

Kinetic Isotope Effects and Transition State Structure for Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase from Plasmodium falciparum

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications

Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase

Continuous Fluorescence Assays for Reactions Involving Adenine

Heat Capacity Changes for Transition-State Analogue Binding and Catalysis with Human 5′-Methylthioadenosine Phosphorylase

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

Microwave spectra, structure, and dynamics of the weakly bound complex, N2 CO2

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

P962: COMMERCIAL TECLISTAMAB IN ANTI‐BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE

The Effects of Low‐Level Laser Light Exposure on Sperm Motion Characteristics and DNA Damage

Abstract 18: Doubled lifespan in APCMin/+ mice by targeting MTAP

P-247 Increased WEE1 Expression Is Predictive of Short Progression-Free Survival, Independent of Standard Prognostic Factors in Multiple Myeloma

An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy

Identifying Causes of Unscheduled Healthcare Interactions and Changes to Patient Disposition in Individuals Receiving Outpatient Commercial Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies

OA-15 Maintenance Therapy Cessation for Multiple Myeloma Patients with Three-Year Sustained MRD Negative Remissions

Aktive Filter

Suchergebnisse filtern